...
首页> 外文期刊>Journal of Medicinal Chemistry >Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
【24h】

Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.

机译:设计,合成和生物学评估一系列氟喹啉蒽嗪与对比对拓扑异构酶II和G四联体的双重作用机制。

获取原文
获取原文并翻译 | 示例

摘要

Topoisomerase inhibitors are important and clinically effective drugs, while G-quadruplex-interactive compounds that disrupt telomere maintenance mechanisms have yet to be proven useful in the clinic. If G-quadruplex-interactive compounds are to be clinically useful, it will most likely be in combination with more established cytotoxic agents. We have previously reported on a family of topoisomerase II inhibitors that also interact with G-quadruplexes. On the basis of previously established structure-activity relationships (SARs) for compounds that are able to inhibit topoisomerase II or interact with G-quadruplex to varying degrees, we have now designed and synthesized four new fluoroquinoanthroxazines (FQAs) that have different profiles of mixed topoisomerase II poisoning effects and G-quadruplex interactions. The biological profiles of the four new compounds were determined with respect to G-quadruplex interaction (polymerase stop and photocleavage assays) and topoisomerase II interaction (DNA cleavage and kDNA decatenation assays), alongside cytotoxicity tests with matched pairs of topoisomerase II-resistant and topoisomerase II-sensitive cells and with telomerase (+) and ALT (+) cell lines (ALT = alternative lengthening of telomeres). From this study, we have identified two FQAs with sharply contrasting profiles of potent G-quadruplex interaction with a weak topoisomerase II poisoning effect, and vice versa, for further evaluation to determine the optimum combination of these activities in subsequent in vivo studies.
机译:拓扑异构酶抑制剂是重要且临床有效的药物,而破坏端粒维持机制的G-四链体相互作用化合物尚未在临床上证明有用。如果G-四链体相互作用化合物在临床上有用,那么它很可能会与更成熟的细胞毒剂联合使用。我们以前曾报道过一系列拓扑异构酶II抑制剂,它们也可与G-四链体相互作用。根据先前建立的能够抑制拓扑异构酶II或与G-四链体相互作用的化合物的结构活性关系(SAR),我们现在设计和合成了四种具有不同混合特性的新型氟喹蒽蒽嗪(FQA)拓扑异构酶II中毒作用和G-四链体相互作用。确定了这四种新化合物的生物学特性,涉及G-四链体相互作用(聚合酶终止和光裂解测定)和拓扑异构酶II相互作用(DNA裂解和kDNA脱模板测定),以及配对的抗拓扑异构酶II和拓扑异构酶配对的细胞毒性测试II型敏感细胞,并带有端粒酶(+)和ALT(+)细胞系(ALT =端粒的替代长度)。从这项研究中,我们确定了两个FQA,它们具有强烈的G-四链体相互作用和较弱的拓扑异构酶II中毒作用,且两者之间形成鲜明的对比,反之亦然,以便进一步评估以确定这些活性在随后的体内研究中的最佳组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号